Charlene M. Prazma

2.7k citations

28 papers · 1.8k indexed · 2 hit papers · h-index 12

Physiology top 1%
Pulmonary and Respiratory Medicine top 2%
Immunology top 5%
Surgery top 10%
Immunology and Allergy top 2%

Co-authors: Héctor Ortega Steven W. Yancey Elisabeth H. Bel Ian Pavord Philip J. Thompson Sally E. Wenzel Oliver N. Keene Thomas F. Tedder
Topics: Asthma and respiratory diseases (25 papers)Respiratory and Cough-Related Research (11 papers)Eosinophilic Esophagitis (7 papers)
Cited by: Physiology Immunology and Allergy Pulmonary and Respiratory Medicine
Journals: New England Journal of Medicine The Journal of Immunology Journal of Allergy and Clinical Immunology
Partner nations: United States United Kingdom Japan

In The Last Decade

Charlene M. Prazma

28 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

2014 1.2k citations Elisabeth H. Bel, Sally E. Wenzel et al. New England Journal of Medicine profile →
Eosinophils in Health and Disease: A State-of-the-Art Review

2021 164 citations Michael E. Wechsler, Ariel Munitz et al. Mayo Clinic Proceedings profile →

Peers

Countries citing papers authored by Charlene M. Prazma

Since Specialization

Citations

This map shows the geographic impact of Charlene M. Prazma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlene M. Prazma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlene M. Prazma more than expected).

Fields of papers citing papers by Charlene M. Prazma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlene M. Prazma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlene M. Prazma. The network helps show where Charlene M. Prazma may publish in the future.

Co-authorship network of co-authors of Charlene M. Prazma

This figure shows the co-authorship network connecting the top 25 collaborators of Charlene M. Prazma. A scholar is included among the top collaborators of Charlene M. Prazma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlene M. Prazma. Charlene M. Prazma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab 2022 ·ERJ Open Research ·Ian Pavord,Roland Buhl,Monica Kraft,Charlene M. Prazma,Robert G. Price,Peter Howarth,Steven W. Yancey	11
2	Eosinophils in Health and Disease: A State-of-the-Art Reviewbreakdown → 2021 ·Mayo Clinic Proceedings ·Michael E. Wechsler,Ariel Munitz,Steven J. Ackerman,Matthew G. Drake,David J. Jackson,Andrew J. Wardlaw,Stephanie K. Dougan,Sergejs Berdnikovs,Florence Schleich,Andrea Matucci,Pascal Chanez,Charlene M. Prazma,Peter Howarth,Peter F. Weller,Peter A. Merkel	164
3	Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes 2021 ·Journal of Asthma and Allergy ·Charlene M. Prazma,Marco Idzko,John Aubrey Douglass,Arnaud Bourdin,Stephen Mallett,Frank C. Albers,Steven W. Yancey	12
4	Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions 2021 ·Respiratory Research ·Peter G. Gibson,Charlene M. Prazma,Geoffrey Chupp,Eric Bradford,Mark Forshag,Stephen Mallett,Steve Yancey,Steven G. Smith,Elisabeth H. Bel	36
5	Mepolizumab improves patient outcomes and reduces exacerbations in severe asthma patients with comorbid upper airways disease 2019 ·Journal of Allergy and Clinical Immunology ·Charlene M. Prazma,Frank C. Albers,Stephen Mallett,(unknown),Steven W. Yancey	7
6	Association of depressive symptoms with health status and markers of uncontrolled severe asthma 2019 ·Allergy and Asthma Proceedings ·Sandhya Khurana,Jeffrey M. Lyness,Stephen Mallett,Linda Nelsen,Charlene M. Prazma,Frank C. Albers,Mark Forshag,Jean‐Pierre Llanos,Steven W. Yancey,Héctor Ortega	5
7	P218 GREATER EFFICACY OF MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA WITH HIGH BASELINE BLOOD EOSINOPHIL COUNTS 2019 ·Annals of Allergy Asthma & Immunology ·Jared Silver,Jean‐Pierre Llanos,Bhabita Mayer,Charlene M. Prazma,Frank C. Albers	1
8	Immunogenicity of Mepolizumab in Patients with Severe Eosinophilic Asthma: Experience from the Clinical Development Program 2018 ·(unknown),(unknown),Guy Brusselle,Koichiro Asano,Robert G. Price,Charlene M. Prazma,Frank C. Albers,Steven W. Yancey,Gerald J. Gleich	2
9	Meta-analysis of Mepolizumab Global Studies Suggest Consistent Therapeutic Response Across a Range of Demographic Sub-groups 2017 ·Journal of Allergy and Clinical Immunology ·Steven W. Yancey,Necdet B. Gunsoy,Eric Bradford,Frank C. Albers,Charlene M. Prazma,Richard Follows,Oliver N. Keene,Ian Pavord	1
10	Austri, a Large Randomized Study in Adolescents and Adults with Asthma, Assessing the Safety and Efficacy of Salmeterol in Combination with Fluticasone Propionate Compared to Fluticasone Propionate Alone 2016 ·Journal of Allergy and Clinical Immunology ·David A. Stempel,Ibrahim Raphiou,Kenneth M. Kral,Anne Yeakey,(unknown),Amanda Emmett,Charlene M. Prazma,Steve Pascoe	2
11	Steroid Sparing Response with Mepolizumab: Durability of Steroid Reduction in Severe Asthma 2016 ·Journal of Allergy and Clinical Immunology ·Charlene M. Prazma,Elisabeth H. Bel,Neil Barnes,Robert G. Price,Frank C. Albers,Steven W. Yancey	4
12	Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone 2016 ·New England Journal of Medicine ·David A. Stempel,Ibrahim Raphiou,Kenneth M. Kral,Anne Yeakey,Amanda Emmett,Charlene M. Prazma,(unknown),Steven Pascoe	104
13	The association between seasonal asthma exacerbations and viral respiratory infections in a pediatric population receiving inhaled corticosteroid therapy with or without long-acting beta-adrenoceptor agonist: A randomized study 2015 ·Respiratory Medicine ·Charlene M. Prazma,James E. Gern,Steven F. Weinstein,Barbara A. Prillaman,David A. Stempel	10
14	Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthmabreakdown → 2014 ·New England Journal of Medicine ·Elisabeth H. Bel,Sally E. Wenzel,Philip J. Thompson,Charlene M. Prazma,Oliver N. Keene,Steven W. Yancey,Héctor Ortega,Ian Pavord	1174
15	Association of CHI3L1 in African-Americans with Prior History of Asthma Exacerbations and Stress 2012 ·Journal of Asthma ·Héctor Ortega,Charlene M. Prazma,Robert Suruki,Hao Li,Wayne H. Anderson	17
16	Controller medications and their effects on asthma exacerbations temporally associated with upper respiratory infections 2010 ·Respiratory Medicine ·Charlene M. Prazma,Kenneth M. Kral,(unknown),Steve Yancey,David A. Stempel	13
17	Long-term Treatment With Fluticasone Propionate (FP) And Salmeterol Via DISKUS® (FSC) Improves Asthma Control Versus Fluticasone Propionate (FP) Alone 2010 ·Rohit Katial,David I. Bernstein,Charlene M. Prazma,William R. Lincourt,David A. Stempel	2
18	CD83 Expression Is a Sensitive Marker of Activation Required for B Cell and CD4+ T Cell Longevity In Vivo 2007 ·The Journal of Immunology ·Charlene M. Prazma,Norihito Yazawa,Yoko Fujimoto,Manabu Fujimoto,Thomas F. Tedder	73
19	CD83 influences cell-surface MHC class II expression on B cells and other antigen-presenting cells 2007 ·International Immunology ·Yoshihiro Kuwano,Charlene M. Prazma,Norihito Yazawa,Rei Watanabe,Nobuko Ishiura,(unknown),Hitoshi Okochi,K. Tamaki,Manabu Fujimoto,Thomas F. Tedder	48
20	Dendritic cell CD83: A therapeutic target or innocent bystander? 2007 ·Immunology Letters ·Charlene M. Prazma,Thomas F. Tedder	48

About Charlene M. Prazma

Charlene M. Prazma is a scholar working on Physiology, Immunology and Allergy and Pulmonary and Respiratory Medicine, having authored 28 papers that have together received 1.8k indexed citations. Recurring topics across this work include Asthma and respiratory diseases (25 papers), Respiratory and Cough-Related Research (11 papers) and Eosinophilic Esophagitis (7 papers). The work is most often cited by research in Physiology (1.5k citations), Immunology and Allergy (318 citations) and Pulmonary and Respiratory Medicine (1.1k citations). Charlene M. Prazma has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Héctor Ortega, Steven W. Yancey, Elisabeth H. Bel, Ian Pavord, Philip J. Thompson, Sally E. Wenzel, Oliver N. Keene, Thomas F. Tedder, David A. Stempel and Manabu Fujimoto. Their work appears in journals such as New England Journal of Medicine, The Journal of Immunology and Journal of Allergy and Clinical Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact